| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 7 | — | 17.2x | Bottom tier | |
Growth | 45 | -86.2% | 7.1% | Around median | |
Quality | 35 | -64.5% | 4.5% | Bottom tier | |
Safety | 55 | — | 2.6x | Around median | |
Capital Return | 15 | 0.00% | 0.19% | Bottom tier | |
Momentum | 41 | 31.4% | 0.5% | Around median | |
Sentiment | 43 | 8 | 3 | Around median |
10-year US Treasury yield 5.29% as of 2026-09-30. Estimates computed from company data and analyst targets, not investment advice.
Stoke Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines that target haploinsufficiency diseases by increasing protein expression from the healthy copy of the gene. Its lead asset is zorevunersen for the treatment of Dravet syndrome, which is being evaluated in the global phase 3 EMPEROR study, while the pipeline includes STK-002 for the treatment of ADOA and a preclinical program for SYNGAP1 disorders. The company continues to record losses, so the stock thesis depends heavily on the regulatory and commercial success of zorevunersen and on the liquidity available to fund development.
In Q2 FY 2026, revenue reached $9.3 million, compared with $6.2 million in Q1 FY 2026, while the net loss widened to $61.6 million from $50.0 million, and loss per share was $0.93 versus $0.79. The provided EDGAR data do not include a figure for gross profit or margin, nor do they present a revenue breakdown by segment; on a latest twelve-month basis, the company recorded revenue of $27.6 million and a net loss of $207.9 million.
The company ended Q2 FY 2026 with cash and marketable investments of $354.3 million, then raised net proceeds of $65.7 million after the quarter ended through the sale of approximately 2.1 million shares under its ATM program, increasing pro forma liquidity to approximately $420 million. According to management, this balance, together with potential Biogen reimbursements for zorevunersen expenses and a potential development milestone payment, supports operations through the drug's potential U.S. launch in early 2028.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $51, within a range of $44 to $58, compared with the stock's 52-week trading range of $18.80 to $40.22; the average target is approximately 27% above the top of that range, with a consensus rating of "Buy." No positive price-to-earnings ratio is available because of the losses, so the valuation is based primarily on the probability of EMPEROR succeeding and reaching approval and launch, weighed against a net loss of $207.9 million during the latest twelve-month period and financing dilution risk.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
The most important catalyst is the phase 3 EMPEROR study readout in Q3 FY 2027. The study enrolled 162 patients, 145 of whom had passed week eight and 60 of whom had completed the week 28 visit as of the August 3, 2026 call, with no treatment discontinuations. The company expects these data to provide the final clinical portion needed to complete the rolling NDA submission for zorevunersen.
75 of 81 patients in the phase 1 and phase 2 studies transitioned into open-label extension studies, and 57 patients remained in them. More than 930 doses were administered, and some patients received treatment for more than five years without new safety findings. Four-year data also showed statistically significant annual improvements in cognition and behavior according to Vineland-3, alongside sustained seizure reductions on top of standard-of-care medications.
The company estimates there are approximately 38 thousand patients in the United States, the United Kingdom, the EU4 countries, and Japan, including approximately 16 thousand in the United States. It estimates that approximately 6 thousand U.S. patients under the age of 25 could be targeted directly at the potential launch, with the care locations of approximately 70% to 80% of this group known. Approximately half of known U.S. patients are also concentrated in the top 50 centers, all of which have experience administering intrathecal therapies.
The company ended Q2 FY 2026 with $354.3 million in cash and marketable investments. After the quarter ended, it raised net proceeds of $65.7 million from the sale of approximately 2.1 million shares, increasing pro forma liquidity to approximately $420 million. According to management, these resources, together with potential Biogen reimbursements and a potential development milestone payment, are sufficient to fund operations through the potential U.S. launch in early 2028, but the recent issuance diluted shareholders' ownership.
STK-002 is the next clinical program and is designed to increase OPA1 protein in ADOA patients with the goal of improving vision. The phase 1 study completed dosing of the first cohort of three patients and advanced to the higher-dose second cohort, with four dose levels planned and early data expected in the first half of FY 2027. The company is also studying five preclinical candidates for SYNGAP1 disorders and hopes to select a development candidate in FY 2027.
The average analyst target is $51, with targets ranging from $44 to $58, while the upper end of the 52-week range was $40.22. However, the company does not have a positive price-to-earnings ratio and recorded a net loss of $207.9 million during the latest twelve-month period. Achieving the analyst targets therefore depends heavily on the EMPEROR results in Q3 FY 2027, followed by the success of the NDA filing, approval, and potential commercial launch.
